Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections.
Acta Med Okayama
; 75(6): 763-766, 2021 Dec.
Article
en En
| MEDLINE
| ID: mdl-34955548
ABSTRACT
The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Urinarias
/
Fluoroquinolonas
/
Antibacterianos
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Acta Med Okayama
Año:
2021
Tipo del documento:
Article